More Biomarkers Needed for Cancer Immunotherapy – The Scientist
The Scientist |
More Biomarkers Needed for Cancer Immunotherapy
The Scientist Determining who will benefit from immunotherapy is an enormous challenge. But by taking a comprehensive view—considering protein biomarkers, mutational changes, and immune cell signatures together—I believe we have a promising path forward. Cancer Immunotherapies Treatment Strategies and Product Pipeline Review 2017 |
